M-14016 Neuron-Specific Enolase (NSE) Quantitative Test Kit

Clinical Significance: NSE exhibits the highest activity in brain tissue cells, intermediate activity levels in peripheral nerves and neuroendocrine tissues, and the lowest levels in non-neural tissues, serum, and cerebrospinal fluid. Excessive expression of NSE is observed in tumors of neuroendocrine origin, particularly small cell lung cancer (SCLC), leading to significantly elevated serum NSE levels.
In patients with small cell lung cancer (SCLC), serum NSE is significantly elevated, with 60-81% of SCLC cases showing increased NSE concentrations.
In neuroblastoma, the positive rate for NSE can reach 96-100%, with significantly elevated values. Serum NSE levels correlate with disease stage and prognosis.
Elevated serum NSE levels can also be observed in a minority of cases with non-small cell lung cancer (NSCLC), medullary thyroid carcinoma, pheochromocytoma, metastatic seminoma, melanoma, and pancreatic neuroendocrine tumors.
Product Specifications: 20 tests per box
Product Shelf Life: Sealed in an aluminum foil bag, the product is valid for 18 months. Once opened, the aluminum foil bag should be used within 1 hour.
Product Storage: Store the test cards at 2°C to 30°C.
 
Usage Scenarios:
Hospitals and Oncology Departments: For diagnosing and monitoring small cell lung cancer (SCLC) by tracking NSE levels, as well as evaluating neuroblastoma, medullary thyroid carcinoma, pheochromocytoma, metastatic seminoma, melanoma, and pancreatic neuroendocrine tumors.
Diagnostic Laboratories: For routine testing of serum NSE levels to aid in the diagnosis and management of various neuroendocrine tumors.
Cancer Screening Programs: For regular screening and monitoring of high-risk populations for early detection of neuroendocrine tumors and other associated malignancies.
Suitable Countries and Regions:
Developed Countries: United States, Canada, Western Europe (e.g., Germany, France, UK), Japan, Australia, etc., where advanced diagnostic tools are widely used for comprehensive cancer management and early detection.
Emerging Markets: China, India, Southeast Asia, Latin America, Eastern Europe, Middle East, etc., where healthcare systems are improving diagnostic capabilities for cancer and expanding access to modern diagnostic tools.
Global Health Programs: International health initiatives focused on enhancing cancer detection and management in low-resource settings.